Primary Prophylaxis for Esophageal Varices
For a patient with known esophageal varices who has never bled, start nonselective beta-blockers (propranolol or nadolol) as first-line therapy, with endoscopic variceal ligation (EVL) reserved as an alternative if beta-blockers are contraindicated or not tolerated.
Treatment Algorithm Based on Variceal Size
For Medium/Large Varices (Most Common Scenario)
Nonselective beta-blockers (NSBBs) are the preferred initial approach because they:
- Reduce all-cause mortality (moderate quality evidence) 1
- Prevent first variceal bleeding 2, 3
- Carry lower risk of serious adverse events compared to EVL 1
- Treat the underlying portal hypertension, not just the varices 3
Specific dosing:
- Propranolol: Start 20-40 mg orally twice daily, adjust every 2-3 days until resting heart rate reaches 55-60 bpm. Maximum 320 mg/day (160 mg/day if ascites present) 2
- Nadolol: Start 20-40 mg orally once daily, adjust every 2-3 days to same heart rate goal. Maximum 160 mg/day (80 mg/day if ascites present) 2
- Carvedilol: Start 6.25 mg once daily, increase after 3 days to 6.25 mg twice daily. Maximum 12.5 mg/day 2
Key advantage of NSBBs: Once started at maximal tolerated dose, no surveillance endoscopy is needed 2, 3.
Alternative: Endoscopic Variceal Ligation (EVL)
Use EVL when:
- Patient has contraindications to beta-blockers (severe asthma, heart block, peripheral vascular disease)
- Patient is intolerant to beta-blockers (symptomatic hypotension, bradycardia, fatigue)
- Patient is non-compliant with medications 2
EVL protocol:
- Repeat every 2-8 weeks until variceal eradication (varices too small to ligate) 2, 4
- First surveillance EGD 1-6 months after eradication
- Then every 6-12 months indefinitely to check for recurrence 2, 3
Critical pitfall: EVL requires ongoing endoscopic surveillance even after successful eradication, unlike beta-blockers 3.
For Small Varices with High-Risk Features
Only treat if BOTH conditions present:
- Small varices on endoscopy, AND
- High-risk features: Child-Pugh class B/C (decompensated cirrhosis) OR red wale marks on endoscopy 2, 4
Treatment: NSBBs (propranolol or nadolol) at doses above 2
If no high-risk features: Surveillance endoscopy every 1-2 years; no prophylactic treatment needed 2.
What NOT to Do
Avoid these therapies for primary prophylaxis (Class III recommendation):
- Nitrates alone (increased bleeding risk) 3
- TIPS or surgical shunts (higher mortality, more encephalopathy) 2, 3
- Endoscopic sclerotherapy (higher mortality than no treatment) 3
- Combination NSBB + EVL for primary prophylaxis (no added benefit, more complications) 2
Common Clinical Pitfalls
Don't combine NSBBs with EVL for primary prophylaxis - Current data do not support combination therapy in patients who have never bled 2. This differs from secondary prophylaxis (after a bleed), where combination is recommended.
Don't use isosorbide mononitrate (ISMN) alone - A multicenter trial showed greater 1- and 2-year probability of first variceal hemorrhage with ISMN versus placebo 3.
Monitor blood pressure carefully - Systolic BP should not drop below 90 mmHg with any beta-blocker regimen 2.
Adjust doses in ascites - Maximum beta-blocker doses are lower in patients with ascites due to altered pharmacokinetics 2.
Consider carvedilol as alternative NSBB - Carvedilol may be superior to traditional NSBBs (moderate quality evidence showing 79% reduction in bleeding risk) 1, though it requires more careful BP monitoring.
Evidence Quality Note
The most recent high-quality guideline is the 2017 AASLD Practice Guidance 2, which supersedes the 2007 Hepatology guidelines 3. The 2020 KASL guidelines 4 and 2022 EASL guidelines 5 provide concordant recommendations. All emphasize NSBBs as gold standard for primary prophylaxis in medium/large varices, with EVL as an acceptable alternative based on patient factors and local expertise.